Antagonism of fludrocortisone by spironolactone and canrenone.
作者信息
Huston G J, Turner P
出版信息
Br J Clin Pharmacol. 1976 Feb;3(1):201-4. doi: 10.1111/j.1365-2125.1976.tb00593.x.
Abstract
摘要
相似文献
1
Antagonism of fludrocortisone by spironolactone and canrenone.螺内酯和坎利酮对氟氢可的松的拮抗作用。
Br J Clin Pharmacol. 1976 Feb;3(1):201-4. doi: 10.1111/j.1365-2125.1976.tb00593.x.
2
Spironolactone and canrenoate-K: relative potency at steady state.螺内酯和坎利酸钾：稳态时的相对效价。
Clin Pharmacol Ther. 1977 May;21(5):602-9. doi: 10.1002/cpt1977215602.
3
4
Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats.
Acta Endocrinol (Copenh). 1979 Jan;90(1):147-56. doi: 10.1530/acta.0.0900147.
5
A comparison of some extra-renal effects of spironolactone and canrenone.螺内酯和坎利酮的一些肾外效应比较。
Br J Clin Pharmacol. 1979 Apr;7(4):385-92. doi: 10.1111/j.1365-2125.1979.tb00950.x.
6
Relation of canrenone to the actions of spironolactone on adrenal cytochrome P-450 dependent enzymes.坎利酮与螺内酯对肾上腺细胞色素P - 450依赖性酶作用的关系。
Endocrinology. 1978 Oct;103(4):1313-20. doi: 10.1210/endo-103-4-1313.
7
Proceedings: Acute and chronic effects of the aldosterone antagonist spironolactone and its main metabolite canrenone on plasma aldosterone concentration, plasma renin activity, serum electrolytes and on the excretion of aldosterone, fluid and electrolytes in rats.研究报告：醛固酮拮抗剂螺内酯及其主要代谢产物坎利酮对大鼠血浆醛固酮浓度、血浆肾素活性、血清电解质以及醛固酮、液体和电解质排泄的急性和慢性影响
Naunyn Schmiedebergs Arch Pharmacol. 1975;287 Suppl:R52.
8
Comparison of single and divided daily dose spironolactone in the control of hypertension.单剂量与分剂量螺内酯控制高血压的比较。
Br J Clin Pharmacol. 1981 Oct;12(4):585-8. doi: 10.1111/j.1365-2125.1981.tb01271.x.
9
Relative potency of prorenoate and spironolactone in normal man.在正常男性体内普乐烯酸酯与螺内酯的相对效价
Clin Pharmacol Ther. 1975 Oct;18(4):391-400. doi: 10.1002/cpt1975184391.
10
[Clinical pharmacology. Pharmacokinetics and affinity of drugs for their receptors, Apropos of anti-aldosterone].[临床药理学。药物的药代动力学及其对受体的亲和力，关于抗醛固酮类药物]
Sem Hop Ther. 1976 Sep-Oct;52(7-8):403-6.
引用本文的文献
1
Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.健康男性口服螺内酯及静脉注射坎利酸钾后坎利酮的药代动力学
Eur J Clin Pharmacol. 1983;25(4):449-53. doi: 10.1007/BF00542109.
2
Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses.
Eur J Clin Pharmacol. 1983;25(2):231-6. doi: 10.1007/BF00543796.
3
Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.螺内酯单剂量和多剂量口服给药后经碱水解的坎利酮及其代谢物的药代动力学。
Eur J Clin Pharmacol. 1984;27(4):441-6. doi: 10.1007/BF00549592.
4
A comparison of some extra-renal effects of spironolactone and canrenone.螺内酯和坎利酮的一些肾外效应比较。
Br J Clin Pharmacol. 1979 Apr;7(4):385-92. doi: 10.1111/j.1365-2125.1979.tb00950.x.
本文引用的文献
1
PHARMACOLOGICAL PROPERTIES OF A MINERALOCORTICOID ANTAGONIST (SC-14266).一种盐皮质激素拮抗剂（SC - 14266）的药理学特性
Arch Int Pharmacodyn Ther. 1964 May 1;149:8-24.
2
QUANTITATION OF MINERALOCORTICOID ACTIVITY AND ANTAGONISM IN NORMAL SUBJECTS.
Metabolism. 1963 Nov;12:1007-11.
3
A comparison of the use of Aldactone and Aldactone A in the treatment of hepatic ascites.安体舒通与螺内酯用于治疗肝腹水的比较。
Gut. 1963 Mar;4(1):16-9. doi: 10.1136/gut.4.1.16.
4
Human assay of electrolyte-active steroids and their antagonists.电解质活性类固醇及其拮抗剂的人体检测。
Clin Sci. 1962 Oct;23:197-202.
5
Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
J Pharmacol Exp Ther. 1973 Jun;185(3):686-95.
Zotero 插件